A Two-part, Phase I, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours or Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs NUC 7738 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors NuCana
- 31 Jan 2019 Status changed from planning to recruiting.
- 11 Dec 2018 New trial record
- 27 Nov 2018 According to NuCana media release, study will start by end-2018.